News Releases

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,

Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZHOU, China , March 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ( "Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage

PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced

Abstract providing early first-in-human data on GC502 accepted for presentation at American Association for Cancer Research (AACR) Annual Meeting 2022 SUZHOU, China , and PALO ALTO, Calif. , Feb. 22, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a

Candidate dual-targeting B cell maturation antigen (BCMA) and CD19 expands Gracell's FasTCAR autologous, next-day manufacturing CAR-T platform SUZHOU , China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ --  Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global

SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,

SUZHOU, China and PALO ALTO, Calif. , Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today